Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | GRK5 | P34947 | 1/20 | 0.42 |
| ▸ | PRKX | P51817 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.41 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188804 | 1.00 | PIK3CA (0.45) | PIK3CAROCK2HPGDSCTSAROCK1 | |
| SCHEMBL29896135 | 0.90 | PIK3CA (0.46) | PIK3CAROCK2ROCK1SOSTTLR2 | |
| SCHEMBL27188828 | 0.90 | PIK3CA (0.46) | PIK3CAROCK2ROCK1SOSTTLR2 | |
| SCHEMBL29896165 | 0.88 | ROCK2 (0.44) | PIK3CAROCK2ROCK1DGAT2 | |
| SCHEMBL27188903 | 0.88 | ROCK2 (0.44) | PIK3CAROCK2ROCK1DGAT2 | |
| SCHEMBL23143264 | 0.88 | PIK3CA (0.43) | PIK3CAROCK2SOSTTLR2 | |
| SCHEMBL29896173 | 0.88 | PIK3CA (0.43) | PIK3CAROCK2SOSTTLR2 | |
| SCHEMBL27188821 | 0.87 | CDK2 (0.48) | PIK3CAROCK2HPGDSROCK1PRKACA | |
| SCHEMBL29896163 | 0.87 | CDK2 (0.48) | PIK3CAROCK2HPGDSROCK1PRKACA | |
| SCHEMBL29896148 | 0.86 | ROCK2 (0.47) | PIK3CAROCK2ROCK1DGAT2SOST |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | PIK3CA 3041/4885ROCK2 4595/4885HPGDS 2677/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | PIK3CA 3041/4885ROCK2 4595/4885HPGDS 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.